cbdMD Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

cbdMD wird ein Gewinn- und Umsatzwachstum von 108.4% bzw. 1.3% pro Jahr prognostiziert, während der Gewinn pro Aktie um 115.6% pro Jahr wachsen soll.

Wichtige Informationen

108.4%

Wachstumsrate der Gewinne

115.6%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	27.3%
Wachstumsrate der Einnahmen	1.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	17 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

cbdMD (NYSEMKT:YCBD) Has Debt But No Earnings; Should You Worry?

Mar 23

This Insider Has Just Sold Shares In cbdMD, Inc. (NYSEMKT:YCBD)

Feb 23

If You Had Bought cbdMD (NYSEMKT:YCBD) Stock A Year Ago, You Could Pocket A 383% Gain Today

Feb 09

We Wouldn't Rely On cbdMD's (NYSEMKT:YCBD) Statutory Earnings As A Guide

Jan 13

Is cbdMD (NYSEMKT:YCBD) Using Debt Sensibly?

Dec 15

Gewinn- und Umsatzwachstumsprognosen

NYSEAM:YCBD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
9/30/2025	22	-3	N/A	N/A	1
9/30/2024	20	-10	N/A	N/A	1
3/31/2024	22	-26	-2	-1	N/A
12/31/2023	23	-24	-3	-2	N/A
9/30/2023	24	-27	-5	-4	N/A
6/30/2023	26	-26	-6	-6	N/A
3/31/2023	29	-56	-8	-8	N/A
12/31/2022	32	-59	-12	-12	N/A
9/30/2022	35	-74	-16	-15	N/A
6/30/2022	37	-63	-18	-17	N/A
3/31/2022	39	-29	-20	-20	N/A
12/31/2021	41	-37	-18	-17	N/A
9/30/2021	44	-26	-14	-14	N/A
6/30/2021	46	-28	-10	-10	N/A
3/31/2021	46	-38	-6	-7	N/A
12/31/2020	44	-10	-9	-8	N/A
9/30/2020	42	12	-12	-11	N/A
6/30/2020	40	31	-19	-17	N/A
3/31/2020	37	15	-23	-20	N/A
12/31/2019	33	-32	-21	-19	N/A
9/30/2019	24	-45	-17	-15	N/A
6/30/2019	8	-60	-10	-10	N/A
3/31/2019	3	-35	-7	-6	N/A
12/31/2018	0	-2	-5	-5	N/A
9/30/2018	0	-2	-6	-6	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: YCBD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: YCBD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: YCBD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: YCBDDie Einnahmen des Unternehmens (1.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: YCBDDie Einnahmen des Unternehmens (1.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von YCBD in 3 Jahren voraussichtlich hoch sein wird

cbdMD Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 12%

No longer forecast to breakeven

cbdMD, Inc. Withdraws Revenue Guidance for the Quarter Ending December 31, 2021

cbdMD, Inc. Revises Sales Guidance for the First Quarter of Fiscal 2022

Consensus EPS estimates fall to -US$0.45

cbdMD, Inc. Provides Net Sales Guidance for the First Quarter of Fiscal 2022

Recent updates

cbdMD Receives Non-Compliance Letter from NYSE American Regarding Shareholders Equity

Consensus revenue estimates fall by 12%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

cbdMD, Inc., Annual General Meeting, Mar 29, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

New major risk - Share price stability

Third quarter 2023 earnings released: US$1.16 loss per share (vs US$24.76 loss in 3Q 2022)

Second quarter 2023 earnings released: US$1.74 loss per share (vs US$4.32 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.082 loss per share (vs US$0.35 loss in 1Q 2022)

cbdMD Appoints Shannon Charles as Chief Marketing Officer

cbdMD, Inc., Annual General Meeting, Feb 16, 2023

Full year 2022 earnings released: US$1.24 loss per share (vs US$0.47 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

cbdMD, Inc. Announces Resignation of Martin Sumichrast as CEO

cbdMD, Inc. Announces Board Changes

Insufficient new directors

cbdMD, Inc. Announces Resignation of Scott Coffman as Co-Chief Executive Officer

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

cbdMD Requests the Food and Drug Administration (FDA) Remove the Drug Exclusion for CBD and Review cbdMD’s Extensive Safety Submission

cbdMD Becomes First American CBD Brand to Receive Validation by the United Kingdom Food Standards Agency

cbdMD, Inc. Becomes the First CBD Company to Earn NSF International’s Certified for Sport Certification

cbdMD, Inc., Annual General Meeting, Mar 11, 2022

cbdMD, Inc. Withdraws Revenue Guidance for the Quarter Ending December 31, 2021

cbdMD, Inc. Launches New Full Spectrum Product Line

cbdMD, Inc. Revises Sales Guidance for the First Quarter of Fiscal 2022

Third quarter 2021 earnings released: EPS US$0.017 (vs US$0.18 loss in 3Q 2020)

Consensus EPS estimates fall to -US$0.45

Second quarter 2021 earnings released: US$0.24 loss per share (vs US$0.41 profit in 2Q 2020)

cbdMD, Inc. Provides Net Sales Guidance for the First Quarter of Fiscal 2022

cbdMD (NYSEMKT:YCBD) Has Debt But No Earnings; Should You Worry?

cbdMD, Inc. Elects Sim Farar as Director

Chairman & Co-CEO recently sold US$240k worth of stock

cbdMD, Inc. Announces Order by Court Staying California Litigation

Independent Director recently sold US$81k worth of stock

cbdMD, Inc. Appoints T. Ronan Kennedy to Serve as Chief Operating Officer

Independent Director notifies of intention to sell stock

Chairman & Co-CEO recently sold US$1.8m worth of stock

This Insider Has Just Sold Shares In cbdMD, Inc. (NYSEMKT:YCBD)

Chairman & Co-CEO notifies of intention to sell stock

Price target raised to US$6.03

First quarter 2021 earnings released: US$0.18 loss per share (vs US$0.47 profit in 1Q 2020)

Revenue and earnings beat expectations

Analysts update estimates

If You Had Bought cbdMD (NYSEMKT:YCBD) Stock A Year Ago, You Could Pocket A 383% Gain Today

Investor sentiment improved over the past week

New 90-day high: US$4.14

Price target raised to US$5.77

cbdMD, Inc., Annual General Meeting, Mar 12, 2021

We Wouldn't Rely On cbdMD's (NYSEMKT:YCBD) Statutory Earnings As A Guide

New 90-day high: US$3.40

Investor sentiment improved over the past week

cbdMD Enters Global Beauty and Skincare Market With Launch of “cbdMD Botanicals”

Price target raised to US$5.53

Revenue beats expectations, earnings disappoint

Full year 2020 earnings released: EPS US$0.28

New 90-day high: US$3.36

Is cbdMD (NYSEMKT:YCBD) Using Debt Sensibly?

New 90-day high: US$3.01

Market bids up stock over the past week

New 90-day low: US$1.84

Pro Group, Inc. Selects cbdMD and Paw CBD as Exclusive Distributor of CBD Brands

cbdMD, Inc Announces Resignation of Mark Elliott as Chief Operating Officer, effective October 01, 2020

Price target raised to US$4.87

Analysts increase EPS estimates to US$0.72

cbdMD, Inc.(AMEX:YCBD) dropped from Russell Small Cap Completeness Index